China SXT Pharmaceuticals SXTC
NASDAQ SXTC
$2.41 -0.55 (-18.58%)
At close: Oct 2, 2026 · 4:00 PM EDT

China SXT Pharmaceuticals (SXTC) Consolidated Net Income (2017 - 2019)

Updated

China SXT Pharmaceuticals (SXTC) reported Consolidated Net Income of -$5.33 million for FY2026 (year ended Mar 31, 2026), compared with -$3.35 million in FY2025.

Analysis

China SXT Pharmaceuticals (SXTC) Consolidated Net Income (2017 - 2019) Analysis & Trends

Dating back to FY2017, China SXT Pharmaceuticals' Consolidated Net Income record includes 10 fiscal years.

  • The FY2026 figure ranks as the lowest annual Consolidated Net Income since FY2023.
  • According to Business Quant data, Consolidated Net Income came in at -$3.35 million in FY2025, -$3.93 million in FY2024, -$7.09 million in FY2023 and -$5.31 million in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Consol Net Inc. (Qtr)
1 Eli Lilly 1,082.65 Bn 1,051.23 Bn 19.71 Bn 7.10 Bn
2 Johnson & Johnson 623.68 Bn 542.21 Bn 17.26 Bn 5.53 Bn
3 AbbVie 459.43 Bn 432.59 Bn 12.70 Bn 3.62 Bn
4 Merck 354.80 Bn 309.23 Bn 12.21 Bn -1.34 Bn
5 Novartis Ag 269.16 Bn 225.03 Bn 11.24 Bn 3.26 Bn
6 Astrazeneca 244.40 Bn 217.97 Bn 12.86 Bn 2.51 Bn
7 Amgen 220.17 Bn 175.57 Bn 7.24 Bn 2.38 Bn
8 Gilead Sciences 183.05 Bn 157.16 Bn 6.22 Bn -10.50 Bn
9 Pfizer 160.27 Bn 107.22 Bn 10.94 Bn -237.00 Mn
10 China SXT Pharmaceuticals 38,844.08 -85.92 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 -1.17 Mn
Dec 31, 2018 1.19 Mn
Mar 31, 2018 -541,655.00
Dec 31, 2017 1.19 Mn
API Access

China SXT Pharmaceuticals Consolidated Net Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=consolidated-net-income&ticker=SXTC&period=max&api_key=YOUR_API_KEY